Skip to main content

Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting


This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-thymocyte globulin, were discussed. The innovative agents and regimens highlighted in this review include abatacept, the first FDA-approved drug for acute GvHD prophylaxis; RGI-2001, which promotes the expansion of regulatory T cells; and cell therapies such as Orca-T and Orca-Q. These advancements provide promising strategies and options for GvHD prevention, offering hope for improved post-transplant patient outcomes in terms of survival rates.

To the editor

Hematopoietic stem cell transplantation (HSCT) can lead to a severe multisystem disorder known as graft-versus-host disease (GvHD), resulting in considerable morbidity and non-relapse mortality (NRM). We reviewed several latest reports on GvHD prophylaxis from the 2022 ASH Annual Meeting (ASH2022).

Novel agents and regimens

Abatacept (ABA), a CD28:CD80/86 co-stimulation blockade, has shown potential in controlling early T cell allo-proliferative escape, a major contributor to breakthrough acute GvHD (aGvHD) following calcineurin inhibitor/methotrexate (CNI/MTX) prophylaxis [1]. ABA + CNI/MTX administration in recipients of 7/8 mismatched unrelated donor (MMUD) grafts, known to carry a higher risk of GvHD-related mortality, demonstrated comparable overall survival (OS) and recurrence-free survival (RFS) rates to those of 8/8 matched unrelated donor (MUD) recipients, thereby improving the risk/benefit ratio for MMUD HSCT [2]. A real-world study further confirmed the finding in adult and pediatric patients [3]. Moreover, ABA/Tacrolimus +- post-transplant cyclophosphamide (PTCy) demonstrates feasibility and promising outcomes with low GvHD rates in matched or mismatched donor peripheral blood stem cell transplantation (PBSCT) [4].

The augmentation of regulatory T cells (Tregs) has gained significant attention as an effective strategy for preventing GvHD while preserving the graft-versus-leukemia (GvL) effect. RGI-2001, a liposomal glycolipid, expands Tregs by activating invariant natural killer cells through CD1d receptor on antigen-presenting cells, thereby modulating GvHD pathogenesis. RGI-2001 administered intravenously with tacrolimus/MTX was effective in preventing aGvHD in individuals receiving grafts from peripheral blood stem cell (PBSC) and bone marrow sources, with a favorable safety profile. Promising results justify the planning of a phase 3 clinical trial to assess the efficacy of the regimen [5]. Orca-T is an innovative immunotherapy with purified donor regulatory T cells to target alloreactive immune responses. Graft composition optimization in HLA-matched PBSCT has shown robust GvL and graft-versus-infection effects, while also reducing the incidence of GvHD and NRM [6]. In the context of haplo-PBSCT, another cellular therapy, Orca-Q, has emerged as a potential prevention option. Administered with single-agent tacrolimus, Orca-Q shows low incidence and severity of GvHD, improved GvHD-free and relapse-free survival (GRFS) rates, and demonstrates clinical superiority even without the use of PTCy. However, the broad adoption of these cell therapies is hindered by the logistical challenge of timely vein-to-vein administration within a restricted 72-hour window, confining their implementation to the specialized institution [7] (Table 1).

Table 1 Applications of novel agents and regimens

PTCy and ATG combination prophylaxis

Combining anti-thymocyte globulin (ATG) and PTCy as prophylaxis against GvHD is a promising strategy, surpassing the limitations of individual administration. ATG-based regimens pose viral infection risks, while PTCy-based prophylaxis is less effective with PBSC grafts. A retrospective study [8] showed that incorporating ATG to the Clo-Baltimore (CloB) regimen with PTCy enhanced GRFS. Another study [9] indicated that a low-dose ATG (2.5 mg/kg)/PTCy (50 mg/kg) regimen holds promise for preventing GvHD following haplo-PBSCT, with a cumulative incidence of aGvHD observed at 30.7%.

Salas et al. conducted trials investigating the use of reduced-dose ATG in various transplantation settings. In Abstract 2127 [10], a comparison was made between two doses of ATG, specifically 4.5 mg/kg and 2 mg/kg, in the context of PBSCT from 10/10 MUD. The higher dose showed a decreased incidence of moderate/severe cGvHD, but was associated with an increased occurrence of infectious complications. Conversely, recipients of the reduced-dose ATG exhibited a trend towards improved 1-year OS. Another study focusing on haplo-PBSCT [11] also reported an increased risk of grade III-IV aGvHD with the administration of the reduced-dose ATG. These studies suggest that the use of low-dose ATG involves certain compromises in prevention efficacy.

Low-dose PTCy has been investigated in elderly patients and those with cardiac comorbidities undergoing haplo-PBSCT [12]. The study suggested that reducing PTCy to 70 mg/kg combined with low-dose ATG is a secure and efficacious strategy, resulting in higher GRFS. Furthermore, the low-dose PTCy led to accelerated immune reconstitution, decreased cumulative incidence of bacteremia, BK-virus associated hemorrhagic cystitis, and cardiac complications, while the risk of aGvHD and cGvHD remained unaffected (Table 2).

Table 2 Clinical outcomes of PTCy and ATG combination prophylaxis

The emergence of novel agents and regimens has expanded the donor pool and allowed the use of different graft sources, including mismatched donors and PBSC, to address patient needs while minimizing the risk of GvHD. For PTCy and ATG combination prophylaxis, future endeavors could focus on investigating lower-dose combination of these agents to achieve the dual goals of minimizing adverse events and maintaining prophylactic efficacy.

Data Availability

Not applicable.


  1. Albanese A, Eran A, Suessmuth Y, Betz K, Bratrude B, Keskula P, et al. Early breakthrough T cell proliferation despite CNI/MTX prophylaxis is a harbinger of Acute GvHD (AGVHD) and is controlled by Abatacept: mechanism of success of the ABA2 AGvHD Prevention Trial. Blood. 2022 Nov;15(Supplement 1):274–5.

  2. Kean LS, Burns LJ, Kou TD, Bond C, Kapikian R, Lozenski K et al. A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following Allogeneic Hematopoietic Cell Transplantation. Blood. 2022 Nov 15;140(Supplement 1):1373–5.

  3. Raghunandan S, Gorfinkel L, Graiser M, Bratrude B, Betz K, Suessmuth Y, et al. Abatacept for the Prevention of GvHD in Pediatric and adult patients receiving 7/8 HLA-Mismatched unrelated transplant for hematologic malignancies: a real-world analysis. Blood. 2022 Nov;15(Supplement 1):7653–5.

  4. Vorobyev VI, Subora AYu, Oleinik YA, Butaev LS, Zherebtsova VA, Kisilichina DG, et al. Abatacept/Tacrolimus or Abatacept/Tacrolimus/Post-Transplant cyclophosphamide are safe and highly effective in preventing graft-versus-host disease in matched or mismatched Donor Peripheral blood stem cell transplantation. Blood. 2022 Nov;15(Supplement 1):7622–3.

  5. Chen YB, Saad A, Farhan SY, Lekakis LJ, Schiller GJ, Yared JA et al. RGI-2001 Infusion for Prevention of Acute GvHD after Allogeneic Hematopoietic Cell Transplantation. Blood. 2022 Nov 15;140(Supplement 1):1877–8.

  6. Oliai C, Hoeg RT, Pavlova A, Gandhi A, Muffly L, Mehta RS et al. Precision-Engineered Cell Therapy Orca-T demonstrates high relapse-free survival at 1 year while reducing graft-versus-host disease and toxicity. Blood 2022 Nov 15;140(Supplement 1):654–6.

  7. Salhotra A, Srour SA, Hoeg RT, Saad A, Meyer EH, Pavlova A, et al. Orca-Q demonstrates favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide. Blood. 2022 Nov;15(Supplement 1):1865–6.

  8. Jullien M, Le Bourgeois A, Peterlin P, Garnier A, Guillaume T, Béné MC et al. Addition of ATG to Clofarabine-Based reduced intensity conditioning regimen with PBSC and ptcy in adults with myeloid malignancies. Blood 2022 Nov 15;140(Supplement 1):10451–2.

  9. Li X, Yang J, Wan L, CAI Y, Zhou K, Huang C, et al. Low-dose antithymocyte globulin plus low-dose post-transplant cyclophosphamide for Prevention of graft-versus-host disease after Haploidentical Peripheral Blood Stem Cell Transplants: a large sample, Long-Term follow-up Retrospective Study. Blood. 2022 Nov;15(Supplement 1):10471–2.

  10. Salas MQ, Santos Carreira A, Atenafu EG, Law AD, Lam W, Pasic I et al. Ptcy-ATG-CSA Vs. ATG-MMF-CSA for GvHD Prevention for 10/10 HLA matched unrelated Donor Allogeneic hematopoietic cell transplantation. Blood 2022 Nov 15;140(Supplement 1):4878–9.

  11. Salas MQ, Santos Carreira A, Atenafu EG, Alfaro Moya T, Law AD, Lam W et al. ATG-Ptcy-CSA for GvHD Prevention in Peripheral Blood Haploidentical hematopoietic cell transplantation for adults with hematological malignancies. Blood 2022 Nov 15;140(Supplement 1):7625–7.

  12. Dulery R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, et al. Reduced post-transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation. Blood. 2022 Nov;15(Supplement 1):10517–8.

Download references


The study is supported by the National Key R&D Program of China (2022YFC2502704), the National Natural Science Foundation of China (82070187) and Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX23_3270).

Author information

Authors and Affiliations



DW designed the study. YX and YC drafted the manuscript. YX and YC prepared the tables. All authors participated in the process of drafting and revising the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yang Xu or Depei Wu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

No, we declare that the authors have no competing interests, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, Y., Xu, Y. & Wu, D. Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol 12, 59 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: